Amy J Johnson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Amy J Johnson

Showing results (11-20 of 121) with videos related to

Pageof 13

Sort By:

Postdoc Journal : a Journal of Postdoctoral Research and Postdoctoral Affairs|December 6, 2016

Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related DiseasesYiming Zhong, Amy J Johnson, John C Byrd, et al.

Current Opinion in Hematology|June 12, 2003

Advances in the therapy of chronic lymphocytic leukemiaAmy J Johnson, Andrew P Mone, Vivek Abhyankar, et al.

Best Practice & Research. Clinical Haematology|August 21, 2007

Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemiaMichael R Grever, David M Lucas, Amy J Johnson, et al.

Experimental & Applied Acarology|February 26, 2011

Mitochondrial genome sequence of Unionicola parkeri (Acari: Trombidiformes: Unionicolidae): molecular synapomorphies between closely-related Unionicola gill mitesDale D Edwards, Lesley E Jackson, Amy J Johnson, et al.

The Biochemical Journal|June 22, 2002

The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risksAmy J Johnson, Ao-Lin Hsu, Ho-Pi Lin, et al.

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|April 16, 2019

Use of mean platelet volume in the assessment of intrauterine infection in newborns with combined thrombocytopenia and leukopenia at birthChu-Yen Chen, Mmeyeneabasi D Essien, Amy J Johnson, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinicianJohn C Byrd, Jeffrey J Jones, Jennifer A Woyach, et al.

Leukemia & Lymphoma|January 9, 2010

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemiaFarrukh T Awan, Amy J Johnson, Rosa Lapalombella, et al.

Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 8, 2018

Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaNeha G Goyal, Kami J Maddocks, Amy J Johnson, et al.

Blood|April 3, 2015

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signalingYuh-Ying Yeh, Hatice Gulcin Ozer, Amy M Lehman, et al.

Pageof 13

Search research articles

Showing results (11-20 of 121) with videos related to

Sort By:

Pageof 13

Postdoc Journal : a Journal of Postdoctoral Research and Postdoctoral Affairs|December 6, 2016

Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related DiseasesYiming Zhong, Amy J Johnson, John C Byrd, et al.

Current Opinion in Hematology|June 12, 2003

Advances in the therapy of chronic lymphocytic leukemiaAmy J Johnson, Andrew P Mone, Vivek Abhyankar, et al.

Best Practice & Research. Clinical Haematology|August 21, 2007

Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemiaMichael R Grever, David M Lucas, Amy J Johnson, et al.

Experimental & Applied Acarology|February 26, 2011

The Biochemical Journal|June 22, 2002

Use of mean platelet volume in the assessment of intrauterine infection in newborns with combined thrombocytopenia and leukopenia at birthChu-Yen Chen, Mmeyeneabasi D Essien, Amy J Johnson, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinicianJohn C Byrd, Jeffrey J Jones, Jennifer A Woyach, et al.

Leukemia & Lymphoma|January 9, 2010

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemiaFarrukh T Awan, Amy J Johnson, Rosa Lapalombella, et al.

Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 8, 2018

Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaNeha G Goyal, Kami J Maddocks, Amy J Johnson, et al.

Blood|April 3, 2015

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signalingYuh-Ying Yeh, Hatice Gulcin Ozer, Amy M Lehman, et al.

Pageof 13